Menu
Menu
The composition of NervGen’s Board and Committees are as follows:
* indicates independent non-executive board member
| Director | Board | Audit | Compensation | Nominating and Corporate Governance | Science |
|---|---|---|---|---|---|
| Brian Bayley* |  |
|
 |
|
|
| Glenn Ives* | |
|
|||
| Randall Kaye* | |
|
|||
| Mike Kelly | |
||||
| Neil Klompas* | |
||||
| Krista McKerracher* | |
|
|
|
|
| Harold Punnett* | |
|
|
||
| Adam Rogers | |
||||
| John Ruffolo* | |
|
|||
| Craig Thompson* | |
|
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com